CV Sciences (CVSI) Return on Capital Employed (2011 - 2026)
CV Sciences' (CVSI) quarterly Return on Capital Employed came in at 31.77% in Q1 2026, up 2838.0% year-on-year from 1.08% in Q1 2025, and down 215.85% quarter-over-quarter from 10.06% in Q4 2025.
CV Sciences (CVSI) Return on Capital Employed (2011 - 2026) Analysis & Trends
CV Sciences has disclosed Return on Capital Employed across 16 years of filings, most recently posting 31.77% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 31.77%, up 2838.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 31.77% (up 2838.0% YoY), and the FY2025 annual result was 8.14%, up 8108.0% from the prior year.
- Return on Capital Employed came in at 31.77% for Q1 2026 at CV Sciences, down from 10.06% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 101.62% in Q4 2023 to a low of 1062.37% in Q4 2022.
- The 5-year median for Return on Capital Employed is 60.15% (2025), against an average of 178.65%.
- Across the five-year window, Return on Capital Employed tumbled 77312 bps in 2022 and surged 116399 bps in 2023, its largest moves.
- CV Sciences' Return on Capital Employed stood at 1062.37% in 2022, then surged by 110 bps to 101.62% in 2023, then sank by 205 bps to 106.83% in 2024, then soared by 91 bps to 10.06% in 2025, then tumbled by 216 bps to 31.77% in 2026.
- The last three Return on Capital Employed figures came in at 31.77% (Q1 2026), 10.06% (Q4 2025), and 38.75% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | CV Sciences | - | - | 1.56 Mn | -31.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.77% |
| Dec 31, 2025 | -10.06% |
| Sep 30, 2025 | -38.75% |
| Jun 30, 2025 | -51.48% |
| Mar 31, 2025 | -60.15% |
| Dec 31, 2024 | -106.83% |
| Sep 30, 2024 | -97.50% |
| Jun 30, 2024 | -95.61% |
| Mar 31, 2024 | -105.15% |
| Dec 31, 2023 | 101.62% |
| Sep 30, 2023 | 57.41% |
| Jun 30, 2023 | 34.59% |
| Mar 31, 2023 | 7.35% |
| Dec 31, 2022 | -1,062.37% |
| Sep 30, 2022 | -701.21% |
| Jun 30, 2022 | -452.92% |
| Mar 31, 2022 | -424.28% |
| Dec 31, 2021 | -289.26% |
| Sep 30, 2021 | -142.30% |
| Jun 30, 2021 | -131.04% |